TRCT
TCRX icon

Tower Research Capital (TRC)’s TScan Therapeutics TCRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.11K Sell
5,063
-1,703
-25% -$1.82K ﹤0.01% 4139
2025
Q4 		$6.77K Sell
6,766
-4,349
-39% -$6.29K ﹤0.01% 4049
2025
Q3 		$20.2K Sell
11,115
-1,456
-12% -$2.58K ﹤0.01% 3296
2025
Q2 		$18.2K Buy
12,571
+1,862
+17% +$2.69K ﹤0.01% 3737
2025
Q1 		$14.8K Buy
10,709
+4,549
+74% +$9.84K ﹤0.01% 3263
2024
Q4 		$18.7K Sell
6,160
-1,889
-23% -$8.56K ﹤0.01% 3240
2024
Q3 		$40.1K Buy
8,049
+3,825
+91% +$23.1K ﹤0.01% 2845
2024
Q2 		$24.7K Buy
+4,224
New +$33.3K ﹤0.01% 3631
2024
Q1 		– Sell
-43
Closed -$251 – 6142
2023
Q4 		$251 Buy
+43
New +$197 ﹤0.01% 5632
2023
Q2 		– Sell
-4,147
Closed -$9K – 6354
2023
Q1 		$9K Sell
4,147
-2,108
-34% -$5K ﹤0.01% 4545
2022
Q4 		$10K Buy
6,255
+212
+4% +$520 ﹤0.01% 4081
2022
Q3 		$18K Sell
6,043
-2,984
-33% -$9.78K ﹤0.01% 4026
2022
Q2 		$28K Buy
9,027
+1,138
+14% +$3.11K ﹤0.01% 3456
2022
Q1 		$22K Buy
7,889
+4,119
+109% +$17.8K ﹤0.01% 3451
2021
Q4 		$17K Buy
+3,770
New +$27.2K ﹤0.01% 3867

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Tower Research Capital (TRC)'s TCRX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its TScan Therapeutics (TCRX) stake by 25% in Q1 2026, selling an estimated $1.82K and leaving 5,063 shares worth $5.11K. The position accounts for ﹤0.01% of the portfolio, ranked #4139.

Tower Research Capital (TRC) first reported a position in TCRX in Q4 2021 and has held it in 15 quarters since. The position peaked at $40.1K in Q3 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Tower Research Capital (TRC) held 5,063 shares of TScan Therapeutics worth $5.11K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,703 TScan Therapeutics shares in Q1 2026, an estimated $1.82K.
  • TScan Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4139 holding.
  • Tower Research Capital (TRC) first reported a position in TScan Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Tower Research Capital (TRC)'s TScan Therapeutics position peaked at $40.1K in Q3 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.